Iberdomide

• MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending
  2024-513889-19-00 Phase III 2 countries Intergroupe Francophone Du Myelome
• A multi-center open-label phase 2 study of Ixazomib, Iberdomide and dexamethasone in elderly patients with multiple myeloma at first relapse Pending
  2024-516257-44-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes
• A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting
  2023-507402-13-00 Phase III 2 countries Universitaetsklinikum Heidelberg AöR
• A Phase 1/2 Study of Etentamig in Combination with a CELMoD Agent for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma Recruiting
  2024-512146-41-00 Phase I/II 3 countries AbbVie Deutschland GmbH & Co. KG
• Iberdomide combined with low-dose cyclophosphamide and dexamethasone: ICON study Recruiting
  2023-508902-66-00 Phase II 1 country Amsterdam UMC
• Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting
  2022-501515-14-00 Phase III 16 countries Celgene Corp.
• CO43923 Master Protocol: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients with Multiple Myeloma CO43923 Substud… Recruiting
  2023-504484-16-00 Phase I/II 4 countries F. Hoffmann-La Roche AG
• Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended
  2024-517008-12-00 Phase III 1 country Fundacion PETHEMA
• Multicenter, phase II, national and open-label study to evaluate Iberdomide-dexamethasone alone or in combination with standard MM treatment… Ended
  2024-518870-15-00 Phase II 1 country Fundacion PETHEMA
• A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended
  2024-510800-35-00 Phase III 16 countries Celgene Corp.
• Iberdomide as maintenance therapy after autologous stem cell transplantation in newly diagnosed multiple myeloma patients Ended
  2024-512354-21-00 Phase II 4 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• A study to decide what is the highest dose of CC-220 to take alone and with other standard of care treatments to assess the side effects, ef… Ended
  2024-510799-19-00 Phase I/II 5 countries Celgene Corp.

Showing 1–12 of 12 trials